Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report

By sjmartinez • October 7, 2022

Kroloff MJ, Holz JB, Stern O, Shepherd CJ, Morrow M, Kayitalire L, Wong DJ. Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report. J Immunother Cancer. 2022 Oct;10(10):e005225. doi: 10.1136/jitc-2022-005225. PMID: 36202556; PMCID: PMC9540849.

Tags: Head and Neck Neoplasms, Hematology/Oncology, immunotherapy, Investigational, Publications, Therapies, Translational Medical Research

[68Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic Lesions

Ludwig V, Maliha PG, Shen J, Tonnelet D, Raman S, Litwin MS, Calais J. [68Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic[...]

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights

Rose MG, Kennedy EB, Abou-Alfa GK, Finn RS, Gade T, Kelley RK, Taddei T, Gordan JD. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update[...]

Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma

Lownik J, Boiarsky J, Birhiray R, Merchant A, Mead M. Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma. Clin Cancer Res.[...]